Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.47 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504234 | 1.00 | CYP1A2 (0.62) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL27689932 | 0.85 | HTT (0.62) | CYP1A2MAPTNPC1RAB9AHTT | |
| SCHEMBL27689875 | 0.80 | TDP1 (0.49) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL27689878 | 0.79 | MMP1 (0.58) | CYP1A2MAPTHTTLMNAPLIN1 | |
| SCHEMBL27689904 | 0.78 | KMT2A (0.48) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL1949536 | 0.77 | MAPT (0.55) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL27709705 | 0.77 | TDP1 (0.52) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL27709603 | 0.77 | EGFR (0.60) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL27709606 | 0.77 | HTT (0.48) | CYP1A2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL143083 | 0.76 | MAPT (0.66) | MAPTNPC1RAB9AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | claimed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| EP-2826770-A1 | Acylguanidine compounds with antiviral activity | Biotron Limited (AU) | 2015-01-21 | — | — | EP | claimed |
| CN-103274970-A | Antiviral compounds and methods | BIOTRON LTD | 2013-09-04 | — | — | CN | claimed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | claimed |
| CN-101827589-A | Hepatitis c antiviral compositions and methods | BIOTROM LTD | 2010-09-08 | — | — | CN | claimed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | claimed |
| JP-2008543886-A | — | — | 2008-12-04 | — | — | JP | claimed |
| CN-101208297-A | Antiviral compounds and methods | BIOTRON LTD (AU) | 2008-06-25 | — | — | CN | claimed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | claimed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | claimed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | CYP1A2 2401/4885MAPT 4416/4885NPC1 560/4885 |
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885MAPT 3427/4885NPC1 290/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3983/4885MAPT 4471/4885NPC1 333/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885MAPT 3427/4885NPC1 290/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3324/4885MAPT 3545/4885NPC1 361/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885MAPT 3427/4885NPC1 290/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3983/4885MAPT 4471/4885NPC1 333/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | CYP1A2 3795/4885MAPT 3702/4885NPC1 340/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3983/4885MAPT 4471/4885NPC1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.